Lunsekimig Clinical Trials (2026): 8 Studies for Asthma & Chronic Obstructive Pulmonary Disease

Where to Participate: All Lunsekimig Trial Sites in the U.S. (159 sites across 31 states)

Every actively recruiting Lunsekimigtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

Lunsekimig clinical trials at a glance: phase × recruitment status

Recruiting Lunsekimig clinical trials (5)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

Lunsekimig clinical trials by indication

Lunsekimig pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

All Lunsekimig trials (8)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

Lunsekimig clinical trials: frequently asked questions

How many Lunsekimig clinical trials are there?

8 Lunsekimig clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 3 are marked completed.

Are Lunsekimig clinical trials recruiting in 2026?

Yes — 5 Lunsekimig trials are actively recruiting in 2026, with 159 U.S. sites across 31 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Lunsekimig being studied for?

Lunsekimig is being studied for Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Dermatitis Atopic. The trials are grouped by indication on this page.

What phase is Lunsekimig in?

Lunsekimig clinical trials span 2 Phase 3, 6 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Lunsekimig clinical trials?

The lead sponsor across the most Lunsekimig trials is Sanofi. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Lunsekimigas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.